Invention:
This technology identifies protease activated receptor-3 (PAR3) and PAR3 inhibitors as a novel target for the treatment of pain.
Background:
Pain is one of the most common reasons in which individuals seek medical attention. Globally, pain affects at least 1.5 billion people, with the incidence rate increasing complementary to age. Current treatments for chronic pain can be harmful to patients in that there is a history of abuse accompanied by intolerable side effects. This technology has the potential to represent a first-in-class therapy for pain once the technology is determined safe and efficient at mitigating pain.
Applications:
- Pain therapeutics
- Mitigation of periodontitis
- Potential for application in cancer
Advantages:
- Potential to represent a first-in-class therapy for pain once the technology is determined safe and efficient at mitigating pain
Status: issued U.S. patent #11,306,130
